A5103238741- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Chemokine receptors and signaling
- Animal Virus Infections Studies
- Cancer Immunotherapy and Biomarkers
- COVID-19 diagnosis using AI
Center for Drug Evaluation and Research
2024
United States Food and Drug Administration
2024
Southern Research Institute
2012
A randomized, double‐blind, placebo‐controlled study (SAVEMORE trial) provided data to support an Emergency Use Authorization (EUA) of anakinra in hospitalized adults with positive results direct severe acute respiratory syndrome‐coronavirus 2 viral testing pneumonia requiring supplemental oxygen (low‐ or high‐flow oxygen) who are at risk progressing failure and likely have elevated plasma soluble urokinase plasminogen activator receptor (suPAR). Currently, the suPAR assay is not...
In terms of its highly pathogenic nature, there remains a significant need to further define the immune pathology SARS-coronavirus (SARS-CoV) infection, as well identify correlates immunity help develop vaccines for severe coronaviral infections. Here we use SARS-CoV infection-reinfection ferret model and functional genomics approach gain insight into SARS immunopathogenesis protection during SARS-CoV-challenge in ferrets previously infected with or immunized virus vaccine. We identified...